Megakaryocytic Neoplasm — Trials

Megakaryocytic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

168 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 30%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (25)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04285086	Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance(SURPASS ET)	active not recruiting	Phase 3	174	PharmaEssentiaINDUSTRY	8	Jul 22, 2026	clinicaltrials
NCT06351631	A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)	recruiting	Phase 3	400	Merck Sharp & Dohme LLCINDUSTRY	6	Apr 2, 2026	clinicaltrials